These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33693077)

  • 1. Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus.
    Nakagaito M; Joho S; Ushijima R; Nakamura M; Kinugawa K
    Circ Rep; 2019 Sep; 1(10):405-413. PubMed ID: 33693077
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship Between HbA1c Level and Effectiveness of SGLT2 Inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus.
    Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
    Int Heart J; 2021 Jul; 62(4):843-849. PubMed ID: 34276009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
    Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
    Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
    Täger T; Atar D; Agewall S; Katus HA; Grundtvig M; Cleland JGF; Clark AL; Fröhlich H; Frankenstein L
    Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment.
    Oh J; Lee SH; Lee CJ; Kang SM
    Korean Circ J; 2021 May; 51(5):399-408. PubMed ID: 33975387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Am J Cardiol; 2021 Jul; 150():65-68. PubMed ID: 34001339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i).
    Kim SH; Chang TI; Mahaffey KW
    Cardiol Ther; 2020 Dec; 9(2):219-225. PubMed ID: 32661684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of SGLT2i on 24-hour ambulatory blood pressure in patients with type 2 diabetes complicating hypertension: a meta-analysis].
    Tian L; Wang QY; Sun RM; Qi MM; Li YX; Gao X; Zhang LQ; Ma X; Shi H; Yu J; Bai F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Oct; 49(10):1000-1011. PubMed ID: 34674438
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospective association of serum adipocyte fatty acid-binding protein with heart failure hospitalization in diabetes.
    Lee CH; Kan AKC; Lui DTW; Fong CHY; Chan DSH; Yuen MMA; Chow WS; Woo YC; Xu A; Lam KSL
    ESC Heart Fail; 2021 Oct; 8(5):3964-3974. PubMed ID: 34355511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure.
    Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
    Int Heart J; 2021 Jul; 62(4):885-890. PubMed ID: 34276019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature.
    Abdelmasih R; Abdelmaseih R; Thakker R; Faluk M; Ali A; Alsamman MM; Hasan SM
    Cardiol Res; 2021 Aug; 12(4):210-218. PubMed ID: 34349861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Inpatient Sodium-Glucose Co-Transporter-2 Inhibitor Use in Patients Hospitalized for Acute Heart Failure.
    Yan CL; Erben A; Sancassani R
    Am J Cardiol; 2024 Jan; 211():175-179. PubMed ID: 37944775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
    Evans M; Achha S; Neslusan C
    Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure.
    Xanthopoulos A; Katsiadas N; Skoularigkis S; Magouliotis DE; Skopeliti N; Patsilinakos S; Briasoulis A; Triposkiadis F; Skoularigis J
    Life (Basel); 2023 Aug; 13(8):. PubMed ID: 37629635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Lou Y; Yu Y; Duan J; Bi S; Swe KNC; Xi Z; Gao Y; Zhou Y; Nie X; Liu W
    Ther Adv Chronic Dis; 2020; 11():2040622320961599. PubMed ID: 33062238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus.
    Unnikrishnan AG; Kalra S; Purandare V; Vasnawala H
    Indian J Endocrinol Metab; 2018; 22(6):837-842. PubMed ID: 30766827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.